Search Ontology:
ChEBI
acalabrutinib
- Term ID
- CHEBI:167707
- Synonyms
-
- (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
- 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide
- 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide
- acalabrutinib
- acalabrutinibum
- ACP-196
- Calquence
- Definition
- A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
- References
-
- CAS:1420477-60-6
- Chemspider:36764951
- DrugBank:DB11703
- Drug_Central:5260
- KEGG:D10893
- PMID:26641137
- PMID:26957112
- PMID:28642301
- PMID:28882879
- PMID:30664965
- PMID:30681658
- PMID:30967367
- PMID:31306750
- PMID:31355927
- PMID:31686856
- PMID:31738609
- PMID:31866282
- PMID:31915195
- PMID:32202637
- PMID:32256115
- PMID:32305083
- PMID:32358576
- PMID:32675912
- PMID:32678359
- PMID:32757302
- PMID:33032842
- PMID:33216986
- PMID:33322571
- PMID:33427570
- PMID:33441177
- PMID:33486852
- PMID:33491779
- PMID:33526860
- PMID:33613932
- PMID:33728735
- PMID:33730844
- Wikipedia:Acalabrutinib
- Ontology
- ChEBI ( EBI )
- is a type of
- has_role
-
Show All 8 Terms
Show first 5 Terms
Phenotype
Phenotype resulting from acalabrutinib
Phenotype where environments contain acalabrutinib
Phenotype modified by environments containing acalabrutinib
Human Disease Model